Recent work suggests that the eukaryotic system responsible for repairing DNA mismatches, and so correcting replication errors, is more complex than was thought; its multiple components have many cellular functions.
Anyone who has tried to type a document understands the three opportunities to do it accurately: selecting the correct keys in the correct order, backing up to edit mistakes as they are made, and correcting the document after completion using spell-checking. Cells accurately replicate their genomes in much the same way: DNA polymerases usually select the correct deoxynucleoside triphosphates for incorporation, occasional mistakes are edited by proofreading exonucleases, and rare errors left behind by the replication machinery are later corrected by the cell's spell-checking machinery, which undertakes post-replication DNA-mismatch repair. Interest in this last process in human cells was greatly stimulated two years ago by studies suggesting that inactivation of mismatch repair may be the initial event leading to certain types of hereditary and sporadic cancers (reviewed in [1] ). Given that many of us will eventually die from some form of cancer, it is no surprise that the pace of studies of mismatch repair has dramatically increased since then. This is especially highlighted by a flurry of exciting and surprising observations in the last few months suggesting that the mismatch-repair system is more complex than was previously thought, and that its multiple gene products participate in a variety of fundamentally important DNA transactions.
The Escherichia coli model
In Escherichia coli, replication and recombination produce mispaired and unpaired bases in DNA that are corrected by the mismatch-repair process outlined in Figure la [2] . Newly replicated DNA is transiently undermethylated at adenines within GATC sequences, providing the signal that allows the repair machinery to distinguish between strands and so to be targetted specifically to the daughter strand that contains the error. Repair is initiated by the binding of a multimer -perhaps a homodimer -of the MutS protein to the mismatch. A multimer of MutL then forms a complex with MutS, ultimately resulting in the activation of a latent, MutH-associated endonuclease that incises the unmodified strand at the hemimethylated GATC site. An experimentally inserted nick in the DNA can alleviate the requirement for MutH incision. ATPdependent excision of nucleotides then proceeds from the nick to around 100 nucleotides past the mismatch, using MutS, MutL, DNA helicase II and an exonuclease. This repair system can operate bidirectionally -that is, the incised GATC site can be either 3' or 5' of the mismatch. Depending on the position of the nick relative to themismatch, one of three possible E. coli exonucleases may perform the excision. Resynthesis of DNA is catalyzed by the DNA polymerase III holoenzyme with single-strand DNA-binding protein as an accessory factor, and the nick is then sealed by DNA ligase to complete the repair.
This methyl-directed mismatch-repair system corrects mismatches and heteroduplexes containing one to four unpaired bases, but does not efficiently correct heteroduplexes containing larger numbers of unpaired bases. The MutS and MutL components also participate in blocking recombination between genetically divergent DNA sequences. Although the precise details of this process are less well understood, it presumably involves interactions of the two proteins with recombination intermediates containing mismatches. In addition to this general mismatch-repair system, E. coli also contains at least two other repair systems for correcting specific mismatched base-pairs that result from deamination of 5-methylcytosine (VSP repair) or from oxidative stress (MutY-dependent repair).
Multiple mismatch-repair genes in eukaryotes
The general mismatch-repair system in human cells [3] shares several features with the E. coli system. The eight possible mismatched base-pairs are repaired with about the same efficiency as in E. coli, and in a strand-specific manner. Although the signal for strand-discrimination in vivo is unknown, repair in vitro can be directed to one strand by a nick in the DNA substrate. The system has the capacity to be bidirectional, and excision and resynthesis occurs between the nick and the mismatch, using proteins whose identity remains to be established. Despite these similarities, studies in yeast, mouse and human cells have identified more than one gene in each with homology to MutS or MutL [1] , suggesting that mismatch repair might be more complex in eukaryotes than in prokaryotes. This has indeed turned out to be the case, as illustrated by more than a dozen publications on eukaryotic mismatch repair in just the last few months.
A major step towards genetically and biochemically dissecting mismatch repair in human cells occurred in 1993. DNA from tumors of patients with a history of a particular type of colon cancer -hereditary non-polyposis colorectal cancer, HNPCC -exhibited elevated genome-wide mutation rates in short repetitive sequences called microsatellites. With this molecular biological marker as a clue to the nature of the defect and the location of HNPCC-susceptibility genes, mutations that could potentially inactivate the mismatch-repair system were quickly identified in four genes, hMlSH2, hMLH1, hPMS1 and hPMS2; in addition, tumor cell lines with mutations in hMSH2 and hMLH1 were found to be defective in mismatch-repair activity.
The hMLH1, hPMS1 and hPMS2 genes are all homologs of the bacterial MutL gene and are closely related at the sequence level to yeast counterparts whose inactivation yields elevated mutation rates. Mutations in these genes are associated with HNPCC (for example, see [4] and references therein). Recently, Li and Modrich [5] restored mismatch-repair activity to an extract made from an hlMLH1-defective tumor cell line by a protein fraction they have designated hMLHot, comprised of hMLH1 and a second protein that is likely to be hPMS2. A role for hPMS2 in mismatch repair is also strongly suggested by two recent publications [6, 7] showing that extracts made from cells with mutations in hPMS2 are defective in mismatch repair. Thus, two (or more) gene products may be required in humans to fulfill the function of one (MutL) in E. coli. Functions for hPMS1 and the other MutL homologs that have been described remain to be established.
The MSH2 gene is a homolog of bacterial MrtS. It encodes a protein that, like MutS, binds in vitro selectively to DNA containing mispaired and unpaired bases ( [8] and references therein). Mutations in hMSH2 are associated with HNPCC and are also found in sporadic tumors (for example, see [9] and references therein). Until recently, it seemed possible that hMSH2 might be the functional equivalent of bacterial MutS. This simple view now needs revision on the basis of new information from the cloning, sequencing and characterization of another gene and its product. This new gene has been designated as p160 [10] or GTBP [11, 12] , the latter for G-T mismatch-binding protein, the property by which the gene product was first identified in 1988. The 160 kDa GTBP protein co-purifies with hMSH2 as a heterodimer, which Drummond et al. [10] have designated hMutSot. Both proteins are required for mismatch binding [11] , and the heterodimer is capable of restoring mismatch-repair activity to the hMSH2-defective LoVo colon tumor cell line [10] . Thus, more than one human gene product fulfills the function performed by MutS in E. coli.
The situation is still more interesting, however. Extracts of GTBP-mutant cell lines [12] do not repair substrates containing mispaired or single unpaired bases, but do repair those with two to five unpaired bases [10, 13] , albeit with reduced efficiency [10] . These data suggest that, in addition to hMutSao for the correction of mismatches and single unpaired bases, human cells may contain one or more additional heteroduplex DNAbinding protein complexes for the repair of larger nonhomologous regions (Fig. c) . What might the protein(s) be? Extracts of hMSH2-mutant LoVo cells are repairdeficient for all substrates examined to date [10, 13] , suggesting that hMSH2 is involved in repairing a wide variety of substrates. Another possibility is suggested by a recent study by Strand et al. [14] demonstrating that a yeast strain with a mutation in MSH3, another MutS homolog, has an elevated mutation rate for dinucleotide repeats but not for non-repetitive sequences. This implies that the cells have a repair defect for substrates containing two unpaired bases but not for those with mismatches, the reciprocal specificity to that of a GTBP mutation in human cells. Thus, a logical candidate protein to replace the question mark alongside hMSH2 in the top of Figure c would be the human homolog of yeast MSH3. Strand et al. [14] also discuss the interesting possibility that there may be mismatch-repair complexes that are specific for the correction of leading-and lagging-strand replication errors.
Although about half of the HNPCC families examined to date have mutations in hMSH2, the situation is very different for the gene encoding its partner in the hMutSao complex, GTBP. Papadopoulos et al. [12] failed to detect GTBP mutations in any of 20 HNPCC families that have yet to be assigned a genetic defect. These unassigned families could obviously have mutations in mismatchrepair genes encoding an exonuclease (for example, see [15] ), helicase or DNA polymerase (for example, see [16] ), or in genes involved in other DNA transactions which, when mutant, lead to elevated mutation rates. But the new studies offer another possibility. The hypothesis that an elevated mutation rate is required in order to obtain the multiple mutations needed for tumor development [17] is consistent with the greatly elevated mutation rates observed in hMSH2-and hMLH1-defective tumor cell lines -but GTBP-defective cells, which retain some capacity to repair substrates with two or more unpaired bases, have more highly elevated mutation rates in non-repetitive and homopolymeric sequences than in dinucleotide repeats ( [12] and references therein). Taken together, these findings imply that a candidate gene whose defect might lead to tumor formation in HNPCC patients would encode a protein required for the repair of substrates with two or more unpaired bases. This protein could conceivably be part of a second hMutS or hMutL complex involving one or more of the other MutS/MutL homologs that as yet have no known functions. The new data are also consistent with the possibility that the risk posed to downstream genes which, if altered, could contribute to tumor progression (for example, the type II TGF[ receptor gene; see [18] ) is proportional to the amount of functionally important repetitive sequences they contain. Might this be part of the explanation for the tissue-specificity of HNPCC-associated tumors?
These musings certainly do not deny the potential involvement of GTBP mutations in cancer, as one of the GTBP-mutant cell lines described by Papadopoulos et al. [12] was derived from a colon tumor, and some tumors have been suggested to manifest a low degree of microsatellite instability. The new data on GTBP-mutant cell lines also have implications for the use of microsatellite instability as a molecular marker of tumor cells. Thus, the absence of microsatellite instability need not indicate a completely functional mismatch-repair system and the presence of microsatellite instability does not automatically imply that repair of mismatches or of unpaired bases is defective.
Multiple functions for mismatch-repair genes
Several recent studies indicate that, as in bacteria, eukaryotic mismatch-repair genes safeguard the genome from promiscuous genetic exchange between DNA strands with less than perfect homology. For example, Selva et al. [19] recently observed strongly elevated rates of mitotic homeologous recombination (between partially divergent sequences) in yeast strains mutant in MSH2 and MSH3, and de Wind et al. [20] have shown that MSH2 mutant mouse cells also have elevated rates of recombination between nonidentical DNA sequences. Interestingly, a deletion of yPMS1 (homologous to hPMS2) had no effect [19] , suggesting that there may be specialization among the various mismatch-repair gene products for the repair of replication errors versus recombination intermediates. One wonders whether GTBP or other lMutS or MutL homologs influence homeologous recombination rates.
Baker et al. [21] have recently generated mice with a null mutation in PMS2 and found that males are infertile. Only abnormal spermatozoa were seen, and examination of axial element and synaptonemal complex formation during prophase of meiosis I indicated abnormal chromosome synapsis. Thus, this mismatch repair gene is also required for male fertility and normal chromosome synapsis. Interestingly, mice that are homozygous for mutations in MSH2 [20] or PMS2 [21] are viable, although the mice do get lymphomas, and microsatellite instability can be detected in DNA from various tissues.
Non-lethal hMLH1 and hPMS2 mutations that inactivate mismatch repair are also found in cell lines derived from HNPCC patients [6] . Curiously, each of these mismatchrepair-defective cell lines is detectably mutant in only one of the two alleles of hMLH1 or hPMS2, in contrast to the usual situation with loss-of-function mutations wherein both alleles are mutant and/or lost. The apparent heterozygosity in these patients may thus indicate that their mutations are 'dominant-negative', interfering with the function of the wild-type protein produced from the other allele -as might be anticipated for one component of a repair pathway involving multiple interacting gene products. The fact that these phenotypically mismatch-repair-defective patients are not rife with tumors at an early age also suggests that the mismatchrepair defect alone is not sufficient for tumorigenesis.
Additional roles for mismatch-repair genes are suggested by other recent studies. Hawn et al. [22] have obtained evidence that the mismatch-repair system may participate in control of the cell cycle at the G2 'checkpoint' that prevents cell-cycle progression in response to treatment with the base analog 6-thioguanine or the DNAdamaging agent N-methyl-N'-nitro-N-nitrosoguanidine. The fact that mismatch-repair-defective cells are highly resistant to alkylating agents has important clinical implications and is consistent with a role for mismatch repair in sensing certain types of DNA damage. Conversely, the p53 protein, known to be a key participant in cell-cycle checkpoint control after DNA damage, has recently been shown to bind selectively to DNA containing unpaired nucleotides [23] . Finally, Mellon and Champe [24] have shown that MutS and MutL are required in E. coli for transcription-coupled nucleotide-excision repair of ultraviolet photoproducts occurring within the DNA of the lactose operon. If similar observations are forthcoming in eukaryotes, this would imply that some mismatch-repair genes may have a role in nucleotide-excision repair, a very different type of repair process [25] .
